[Correspondence] Lessons from the Multidomain Alzheimer Preventive Trial – Authors' reply

We thank Hussein Yassine and Lon Schneider for their interest in the MAPT trial1 and their analysis of its contribution to research on the prevention of cognitive decline. Given the nature of the intervention, it would have been virtually impossible for the multidomain component of our intervention to be double-blind. We acknowledge that this is a limitation of our study, as underlined in the discussion section of the Article.1 However, we made every effort to make sure that the trial was at least single-blind by using blinded evaluators and asking participants not to disclose their multidomain group assignment to these evaluators.

Source: Lancet Neurology - July 12, 2017 Category: Neurology Authors: Nicola Coley, Sandrine Andrieu, MAPT Study Group Tags: Correspondence Source Type: research